Sinphar Group (杏輝醫藥集團) on Friday held a biomedical forum in Taipei about pancreatic cancer treatment and its new drug development efforts, saying Folfirinox is still superior in first-line chemotherapy treatment for late-stage pancreatic cancer compared with other drugs.
Among first-line treatments for pancreatic cancer, clinical trials have shown that Folfirinox has produced an overall survival period of 11.1 months among patients, exceeding the 6.8 months of the standard gemcitabine chemotherapy, the company said.
About 340,000 people worldwide are diagnosed with pancreatic cancer each year and the number has continued to increase every year, according to American Society of Clinical Oncology data.
Pancreatic cancer is the eighth-leading cause of death from cancer in Taiwan, with 1,948 people dying from pancreatic cancer in 2015, Health Promotion Administration data showed.
While Folfirinox is designed for patients who require continued treatment, but have exhausted other first-line options, the regimen has a limited market in Taiwan as it is not covered by the National Health Insurance program and therefore is less prescribed by physicians, Sinphar said.
Despite rising use in Europe and North America as well as a track record of longer survival periods, there are few pancreatic cancer patients in Taiwan who have elected to pay out of pocket to undergo treatment with Folfirinox, SynCore Biotechnology Co (杏國新藥) general manager Su Muh-hwan (蘇慕寰) said on the sidelines of the forum.
SynCore, the group’s new drug development subsidiary, is developing a second-line treatment for pancreatic cancer, SB05 PC, which has begun its global phase III study, Su said.
SynCore’s board last month approved plans to provide NT$20 million (US$687,262) toward sponsoring Folfirinox treatments overseen by the National Health Research Institutes, as well as covering the cost of the regimen for patients under the care of select hospitals working with the company.
Another reason Folfirinox has not been widely prescribed in Taiwan is due to differences between Taiwanese doctors and their counterparts in Europe and North America, Su said.
European and North American physicians are more likely to prescribe the drug because it leads to a longer survival period for patients, while Taiwanese doctors are apprehensive about the lack of a readily available second-line treatment if the disease continues to progress, he said.
Despite its superior survival results, that Folfirinox is comprised of four chemotherapy drugs means that patients are more heavily affected by its higher toxicity, Su said, adding that the drug is more widely prescribed to younger European and North American patients who generally are in better physical condition.
The domestic unit of the Chinese-owned, Dutch-headquartered chipmaker Nexperia BV will soon be able to produce semiconductors locally within China, according to two company sources. Nexperia is at the center of a global tug-of-war over critical semiconductor technology, with a Dutch court in February ordering a probe into alleged mismanagement at the company. The geopolitical tussle has disrupted supply chains, with some carmakers reportedly forced to cut production due to chip shortages. Local production would allow Nexperia’s domestic arm, Nexperia Semiconductors (China) Ltd (安世半導體中國), to bypass restrictions in place since October on the supply of silicon wafers — etched with tiny components to
Singapore-based ride-hailing and delivery giant Grab Holdings Ltd has applied for regulatory approval to acquire the Taiwan operations of Germany-based Delivery Hero SE's Foodpanda in a deal valued at about US$600 million. Grab submitted the filing to the Fair Trade Commission on Friday last week, with the transaction subject to regulatory review and approval, the company said in a statement yesterday. Its independent governance structure would help foster a healthy and competitive market in Taiwan if the deal is approved, Grab said. Grab, which is listed on the NASDAQ, said in the filing that US-based Uber Technologies Inc holds about 13 percent of
Taiwan is open to joining a global liquefied natural gas (LNG) program if one is created, but on the condition that countries provide delivery even in a scenario where there is a conflict with China, an energy department official said yesterday. While Taiwan’s priority is to have enough LNG at home, the nation is open to exploring potential strategic reserves in other countries such as Japan or South Korea, Energy Administration Deputy Director-General Chen Chung-hsien (陳崇憲) said. While the LNG market does not have a global reserve for emergencies like that of oil, the concept has been raised a few times —
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday received government approval to deploy its advanced 3-nanometer (3nm) process at its second fab currently under construction in Japan, the Ministry of Economic Affairs said in a news release. The ministry green-lit the plan for the facility in Kumamoto, which is scheduled to start installing equipment and come online in 2028 with a monthly production capacity of 15,000 12-inch wafers, the ministry said. The Department of Investment Review in June 2024 authorized a US$5.26 billion investment for the facility, slated to manufacture 6- to 12nm chips, significantly less advanced than 3nm process. At a meeting with
RSS